Last reviewed · How we verify
ACEI omission
ACEI omission refers to the clinical practice of withholding or not prescribing ACE inhibitors, typically studied as a comparative intervention rather than a drug itself.
ACEI omission refers to the clinical practice of withholding ACE inhibitors, typically studied as a comparative intervention rather than a drug product itself. Used for Comparative intervention in clinical trials (not a marketed drug product).
At a glance
| Generic name | ACEI omission |
|---|---|
| Also known as | quinapril, Accupril, perindopril, Aceon, ramipril |
| Sponsor | University of Nebraska |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This is not a pharmaceutical agent but rather a clinical decision or study design element examining outcomes when ACE inhibitors are omitted from treatment regimens. It is used in comparative effectiveness research to evaluate the impact of ACE inhibitor use versus non-use in patient populations, particularly those with cardiovascular or renal conditions.
Approved indications
- Comparative effectiveness research in cardiovascular and renal disease management
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACEI omission CI brief — competitive landscape report
- ACEI omission updates RSS · CI watch RSS
- University of Nebraska portfolio CI